Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma

(2016) Trung N. Tran et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Severe asthma: from characteristics to phenotypes to endotypes

(2012) S. Wenzel   CLINICAL AND EXPERIMENTAL ALLERGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome

(2011) Jan Lötvall et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program

(2009) Wendy C. Moore et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cluster Analysis and Clinical Asthma Phenotypes

(2008) Pranab Haldar et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE